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Vena Cava Filter
S. William Stavropoulos, MD, Ronald F. Sing, DO, Fakhir Elmasri, MD,
Mitchell J. Silver, DO, Alex Powell, MD, Frank C. Lynch, MD,
Ahmed Kamel Abdel Aal, MD, Alexandra J. Lansky, MD,
Richard A. Settlage, MS, and Bart E. Muhs, MD, PhD, for
the DENALI Trial InvestigatorsABSTRACT
Purpose: To assess safety and effectiveness of a nitinol retrievable inferior vena cava (IVC) ﬁlter in patients who require caval
interruption to protect against pulmonary embolism (PE).
Materials and Methods: Two hundred patients with temporary indications for an IVC ﬁlter were enrolled in this prospective,
multicenter clinical study. Patients undergoing ﬁlter implantation were to be followed for 2 years or for 30 days after ﬁlter
retrieval. At the time of the present interim report, all 200 patients had been enrolled in the study, and 160 had undergone a
retrieval attempt or been followed to 6 months with their ﬁlter in place. Primary study endpoints included technical and clinical
success of ﬁlter placement and retrieval. Patients were also evaluated for recurrent PE, new or worsening deep vein thrombosis,
and ﬁlter migration, fracture, penetration, and tilt.
Results: Clinical success of placement was achieved in 94.5% of patients (172 of 182), with a one-sided lower limit of the 95%
conﬁdence interval of 90.1%. Technical success rate of ﬁlter placement was 99.5%. Technical success rate of retrieval was 97.3%;
108 ﬁlters were retrieved in 111 attempts. In two cases, the ﬁlter apex could not be engaged with a snare, and one device was
engaged but could not be removed. Filter retrievals occurred at a mean indwell time of 165 days (range, 5–632 d). There were no
instances of ﬁlter fracture, migration, or tilt greater than 151 at the time of retrieval or 6-month follow-up.
Conclusions: In this interim report, the nitinol retrievable IVC ﬁlter provided protection against pulmonary embolism, and the
device could be retrieved with a low rate of complications.
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AE = adverse event, AP = anterior–posterior, CEC = clinical events committee, CI = conﬁdence interval, CSP = clinical success of
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Stavropoulos et al ’ JVIR1498 ’ Interim Analysis of the Prospective, Multicenter DENALI TrialManagement of venous thromboembolic disease, includ-
ing deep vein thrombosis (DVT) and pulmonary embo-
lism (PE), creates a burden to the health care system that
results in signiﬁcant patient morbidity and mortality
rates approaching 300,000 per year from PE. The
associated costs of treating venous thromboembolic
disease have increased to more than $7.5 billion per
year in the United States (1,2). Pharmacologic manage-
ment with anticoagulant agents such as low molecular
weight heparin or vitamin K antagonists (eg, warfarin) is
standard therapy for venous thromboembolic disease.
However, for some patients, anticoagulation may be
contraindicated or ineffective or can result in bleeding
complications that require discontinuation of therapy.
Permanent IVC ﬁlters have been shown to reduce the
initial risk of PE and provide long-term protection, but
the effects of long indwell times increase the risk of DVT
and other complications, including caval obstruction,
ﬁlter fracture, or migration (3–7).
Retrievable IVC ﬁlters were developed to provide
protection from PE for patients who temporarily need
an IVC ﬁlter because they can be removed when no longer
needed, potentially eliminating the long-term risks of a
permanent ﬁlter. The United States Food and Drug
Administration (FDA) initially changed the indications
for use of three previously approved permanent ﬁlters to
allow for retrieval (8,9), which was followed by the
development of a new generation of optional vena cava
ﬁlters designed with the option for retrieval when the
period of increased risk for PE has passed or contra-
indications to anticoagulation are resolved (10–17).
The present study was designed to evaluate placement
and retrieval of a new retrievable IVC ﬁlter in patients
with documented DVT, PE, or temporary increased risk
of PE requiring ﬁlter placement.MATERIALS AND METHODS
The DENALI trial is a prospective, multicenter, non-
randomized, single-arm study conducted at 21 centers in
the United States. The protocol was approved by the
institutional review board or ethics committee at each
enrolling institution, and all study procedures were
conducted in accordance with the guidelines of good
clinical practice and applicable FDA regulations. The
DENALI trial was registered on clinicaltrials.gov (ID
code NCT01305564) before the start of the study.
Patients eligible for inclusion were at least 21 years
old, had documented evidence of DVT or PE at place-
ment, or were at risk of PE with a clinical indication for
IVC ﬁlter placement as a result of contraindication to or
failure of anticoagulation (18). In addition, patients had
an IVC diameter of no more than 28 mm and had
adequate venous anatomy to allow placement and
retrieval of an IVC ﬁlter. Women were required to
have a negative pregnancy test, be surgically sterile, orbe postmenopausal before enrollment. Patients were
excluded from the trial if they had previously received
an IVC ﬁlter; had a duplicated or left-sided IVC; or had
an anatomic anomaly that the operator believed might
impact the insertion, indwell stability, or retrieval of the
ﬁlter. In addition, patients were excluded if they exhib-
ited signs of renal failure (serum creatinine level 4 2.0
mg/dL) and were undergoing dialysis, had an uncorrect-
able bleeding diathesis, had a life expectancy of less than
25 months, or had a known allergy or sensitivity to study
materials (eg, nickel or titanium) or iodinated contrast
media that was not amenable to treatment with steroid
agents, antihistamine agents, or other medications before
device implantation.Study Endpoints
The primary objectives of the study were to assess the
technical and clinical success of ﬁlter placement and
retrieval. Technical success of ﬁlter placement was
deﬁned as placement of a ﬁlter that provided sufﬁcient
mechanical interruption in the vena cava to prevent PE.
Technical success of ﬁlter retrieval was achieved if the
ﬁlter was retrieved completely intact without immediate
complications. Clinical success of ﬁlter placement (CSP)
was deﬁned as freedom from subsequent PE, ﬁlter mi-
gration, vena cava occlusion, ﬁlter- or procedure-related
death, adverse events associated with ﬁlter placement, or
failure of ﬁlter placement. As per Society of Interven-
tional Radiology (SIR) guidelines, clinical success was
achieved if the lower bound of the 95% conﬁdence
interval (CI) was greater than 80%. Clinical success of
ﬁlter retrieval was achieved if the ﬁlter was retrieved
without complications that required intervention (18,19).
In addition, the overall clinical experience was eval-
uated by assessing recurrent PE to 6 months after ﬁlter
placement or 1 month following ﬁlter retrieval, new or
worsening DVT to 6 months, and the rate of ﬁlter
complications such as migration, fracture, penetration,
or tilt. Recurrent PE was deﬁned as any PE occurring
after ﬁlter placement documented by pulmonary arte-
riography, cross-sectional imaging, altered ventilation/
perfusion lung scan, or autopsy. Worsening DVT was
deﬁned as an extension of DVT to a new venous segment
in patients with documented evidence of DVT at base-
line. Filter migration was deﬁned as a change in ﬁlter
position of more than 2 cm (cranial or caudal direction)
compared with the baseline deployed position assessed
by plain-ﬁlm radiography, computed tomography (CT),
or venography. Filter fracture was deﬁned as a loss of
structural integrity of the ﬁlter (ie, breakage or separa-
tion of ﬁlter components) documented by imaging or
autopsy. Filter penetration was deﬁned as penetration of
a ﬁlter leg or arm more than 3 mm outside the vena cava
wall as measured by CT, ultrasound (US), or venogra-
phy, or noted during autopsy. Filter tilt was deﬁned as
greater than 151 tilt of the ﬁlter off the IVC axis. All
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rence, were reported by the study investigators and
reviewed and adjudicated by an independent clinical
events committee (CEC).
Study Device
Patients who met the criteria for study enrollment
received a retrievable vena cava ﬁlter (Denali Retriev-
able Vena Cava Filter, Bard Peripheral Vascular,
Tempe, AZ) designed to mechanically prevent PE
(Fig 1). The nitinol IVC ﬁlter consisted of 12 shape-
memory struts laser-cut from a single piece of nitinol
(nickel-titanium alloy). The struts were designed to form
two levels of embolic ﬁltration: six ﬁlter legs provided
the lower level of ﬁltration and six ﬁlter arms provided
the upper level. The ﬁlter legs were designed with cranial
and caudal anchors to resist superior and inferior
migration and, if needed, provide permanent attachment
to the vena cava wall; however, the legs were also
designed to limit penetration through the wall of the vena
cava, allowing percutaneous removal if the ﬁlter was no
longer needed. The ﬁlter was implanted percutaneously
through a femoral or jugular vein approach, and the device
was intended for use in an IVC as large as 28 mm in
diameter. The delivery system was composed of an
introducer sheath, dilator, and preloaded ﬁlter with pusher.
The sheath was 55 cm long with an 8.4-F inner diameter,
and the dilator was compatible with an 0.035-inch wire.
Filter Placement, Filter Retrieval, and
Imaging Analyses
Patients referred for retrievable vena cava ﬁlter place-
ment were screened for inclusion in the study, completedFigure 1. Image of the Denali IVC ﬁlter.written informed consent to participate in the trial, and
received preprocedural imaging assessments. US screen-
ing of the internal jugular veins was performed before
ﬁlter placement to assess potential pathways for ﬁlter
retrieval. In addition, bilateral lower-extremity US
examinations were performed to assess the presence of
lower-extremity DVT.
A patient was considered enrolled in the study when
the ﬁlter introducer sheath was inserted. An angiogram
of the vena cava was obtained before ﬁlter deployment,
with a known reference marker in the ﬁeld of view to
assess the vena cava diameter. The ﬁlter was advanced
through the sheath by using the pusher, and then the
pusher was used to ﬁx the ﬁlter in place while it was
unsheathed and deployed into the IVC. After device
placement, anterior–posterior (AP) and lateral digital
subtraction angiograms of the vena cava were obtained.
Phone consultations were performed at 3, 12, 18, and
24 months after the procedure to assess whether the ﬁlter
should be retrieved, to document the recurrence of PE or
DVT, and to determine whether the patient experienced
ﬁlter-related complications. At 6 months after place-
ment, a follow-up clinic visit was required. A physical exa-
mination, a lower-extremity US examination to assess the
presence or change in lower-extremity DVT versus base-
line, and plain radiographic ﬁlm imaging of the abdomen
to evaluate IVC ﬁlter position were performed.
If a patient was no longer at risk of PE requiring IVC
ﬁltration or could tolerate anticoagulation, the patient
was referred for ﬁlter removal. Before attempted ﬁlter
retrieval, AP and lateral digital subtraction angiograms of
the vena cava were obtained. The ﬁlter retrievals were
performed by using a dual-sheath technique with a 9-F,
70-cm Flexor sheath (Cook, Bloomington, Indiana) inside
a 12-F, 40-cm Flexor sheath (Cook). A loop snare was
used to engage the ﬁlter hook and remove the ﬁlter. An
angiogram of the vena cava was obtained after retrieval.
Patients were evaluated in the clinic at 30 days after
retrieval to assess overall health status, the recurrence of
PE or DVT, and ﬁlter-related complications based on
SIR clinical practice guidelines (20). All IVC ﬁlter
insertion, 6-month follow-up, and retrieval images were
submitted to the Yale Angiographic Core Laboratory
(Yale University, New Haven, Connecticut) for independ-
ent review and analysis. Each image set was reviewed by
the staff radiologist and the laboratory director.Statistical Analysis
SIR reporting standards were used to evaluate the IVC
ﬁlters (21,22). This study included 200 patients
implanted with a Denali ﬁlter. The sample size was
based on plans to analyze data on the ﬁrst 65 patients
followed to 6 months after ﬁlter placement and 50
patients completing the 30-day postretrieval visit. The
inclusion of 65 patients ensured that, if the observed rate
of CSP was a minimum of 89%, the lower, one-sided
Table 1 . Baseline Patient Characteristics, Medications, History,
and Disease Status
Variable
All Patients
(N ¼ 200)
Retrieved Filter
(n ¼ 108)
Sex, M/F (%)
Male 126 (63) 69 (63.9)
Female 74 (37) 39 (36.1)
Mean age (y) 56.6  15.63 56.4  14.88
Weight (kg) 97.4  26.00 99.2  26.05
BMI (kg/m2) 32.9  9.07 33.8  9.44
BMI 4 30 119 (59.5) 68 (63.0)
Race, n (%)
White 164 (82.0) 93 (86.1)
Black 31 (15.5) 12 (11.1)
Native American 1 (0.5) 0
Other 4 (2.0) 3 (2.8)
TED status
Contraindication of
anticoagulation
66 (33.0) 35 (32.4)
Complication of
anticoagulation
9 (4.5) 2 (1.9)
Failure of anticoagulation 20 (10.0) 4 (3.7)
TED in the absence of the 23 (11.0) 9 (8.3)
Stavropoulos et al ’ JVIR1500 ’ Interim Analysis of the Prospective, Multicenter DENALI Trial95% conﬁdence bound would be no lower than 80%. All
subjects enrolled in the study will be followed to 24
months or 30 days after retrieval. All endpoints were
analyzed per patient and on an intent-to-treat (ITT)
basis. The ITT population included all patients followed
for at least 6 months or followed for at least 30 days
after ﬁlter retrieval. Demographic and baseline charac-
teristics (eg, sex and age) were summarized, summary
statistics for categoric variables include frequency counts
and percentages, and means and standard deviations are
provided for continuous variables. Primary endpoints
were summarized descriptively and reported as estimated
proportions with associated 95% CIs. The composite
coprimary endpoint of CSP was reported as the propor-
tion of the ITT population with CSP with a one-sided
lower 95% CI. If the lower 95% CI for the observed
clinical success rate was greater than or equal to 80%, it
was concluded that the endpoint was successfully ach-
ieved. The rate was selected based on a combined total
of 20% representing the ﬁve elements suggested by SIR
that contribute to clinical failure: technical failure (3%),
recurrent PE (5%), ﬁlter embolization (o 1%), IVC
occlusion (10%), insertion-related complications (1%),
and death (o 1%) (18,19).above
No TED (prophylactic) 80 (40.0) 58 (53.7)
Primary thrombotic risk factor
for ﬁlter placement
Surgery 87 (43.5) –
Trauma 41 (20.5) –
Hypercoagulopathy 44 (22.0) –
Cancer 10 (5.0) –
Stroke (past 6 mo) 3 (1.5) –
Other 15 (7.5) –
Values presented as means  SD where applicable.
Values in parentheses are percentages.
BMI ¼ body mass index, TED ¼ thrombotic disease.RESULTS
Pretreatment Demographics and Patient
Characteristics
Between June 23, 2011, and May 14, 2013, 200 patients
underwent IVC ﬁlter placement: 63% (n = 126) were
male and 37% (n = 74) female, with an overall mean age
of 56.6 years (range, 18–89 y). One hundred twenty
patients (60%) were diagnosed with DVT or PE at the
time of IVC ﬁlter placement, and 80 (40%) were at
temporarily increased risk of PE but did not have active
thromboembolic disease at the time of ﬁlter placement.
Primary thromboembolic risk factors for temporary
ﬁlter placement included surgery (43.5%), trauma
(20.5%), and hypercoagulopathy (22%; Table 1).
Filter Placement
The mean procedure time for ﬁlter placement was 17.8
minutes  10.3 (range, 3–90 min), and the mean ﬂu-
oroscopy time was 3.6 minutes  3.1 (range, 1–32 min;
Table 2). The most common vascular access site used for
placement was the right common femoral vein (55%),
followed by the right internal jugular vein (35%). The
mean IVC diameter at the site of placement was 22.2
mm  3.1 (range, 12.7–27.8 mm).
Postprocedure Follow-up
The disposition of the 200 patients in the DENALI
study is outlined in Figure 2. Filters were retrieved in 108
patients, and 24 patients were removed from the study
before completion; of these, 14 patients died from causesunrelated to the IVC ﬁlter, one withdrew consent to
participate in the study, seven were lost to follow-up,
and two were discontinued from the study at the
discretion of the investigator. Forty-nine patients still
had an indication for the ﬁlter to remain in situ during
their 6-month follow-up clinic visit. Filters remained
implanted in 92 patients.
Technical and Clinical Success of
Placement
Technical success of ﬁlter placement was achieved in
99.5% (n ¼ 199) of the patients enrolled in the trial
(Table 2). One ﬁlter was introduced but could not be
deployed, and a second ﬁlter was successfully deployed in
the patient without clinical sequelae. In addition, a
successfully deployed device was moved inadvertently
with a guide wire during postprocedural imaging; this
was not considered a technical failure, and the ﬁlter was
immediately retrieved and replaced with a second ﬁlter at
Table 2 . Filter Placement and Retrieval Technical Success and
Procedural Data
Variable
All Patients
(N ¼ 200)
Retrieved
Filters
(n ¼ 108)
Placement procedural data
Technical success of placement* 199 (99.5) –
95% CI 97.2–100 –
Placement time (min)
Mean  SD 17.8  10.32 –
Median 17 –
Range 3–90 –
Fluoroscopy time (min)
Mean  SD 3.6  3.14 –
Median 3.0 –
Range 1–32 –
IVC diameter (mm)†
Mean  SD 22.2  3.10 –
Median 22.5 –
Range 12.7–27.8 –
Vascular access sites
Right common femoral vein 110 (55.0) –
Right jugular vein 70 (35.0) –
Left common femoral vein 18 (9.0) –
Left jugular vein 2 (1.0) –
Hospitalization status
Inpatient 160 (80.0) –
Outpatient 40 (20.0) –
Retrieval procedural data
Technical success of retrieval‡ – 108 (97.3)
95% CI – 92.3–99.4
Indwell time (d)
Mean  SD – 165  113.9
Median – 147
Range – 5–632
Retrieval time (min)§
Mean  SD – 21.3  15.65
Median – 20
Range – 4–118
Fluoroscopy time (min)
Mean  SD – 6.4  8.61
Median – 4.0
Range – 1–69
IVC diameter (mm)||
Mean  SD – 22.0  2.98
Median – 21.9
Range – 15.6–27.4
Filter retrieval access site
Right jugular vein – 108 (100)
Values in parentheses are percentages.
CI ¼ conﬁdence interval, IVC = inferior vena cava, SD ¼ standard
deviation.
*One ﬁlter was introduced but could not be deployed. A second
ﬁlter was successfully deployed in the patient without clinical
sequelae.
†Quantitatively measured by the core laboratory after ﬁlter
placement.
‡One hundred eight of 111 retrieval attempts were successfully
completed. In two cases, the operator was unable to engage the
ﬁlter apex with a snare. One device was engaged with a snare,
but could not be removed.
§For all successful retrievals (N ¼ 108).
||Quantitatively measured by the core laboratory after retrieval.
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placement failure, complications associated with ﬁlter
placement, subsequent PE, ﬁlter embolization, vena
cava occlusion, or ﬁlter- or procedure-related death—
was achieved in 94.5% of patients (172 of 182; 95% CI,
90.1%–97.3%) in the ITT population (Table 3). There
were 11 events reported in 10 patients that impacted CSP,
including three in patients with access-site pain and
discomfort that did not lead to clinical sequelae (two
with pain at the access site; one with a bruise and
discomfort), six in patients with recurrent PE (one of
whom also experienced caval occlusion), and one techni-
cal deployment failure (described earlier). There were no
reported ﬁlter embolizations or ﬁlter- or procedure-related
deaths. Per SIR guidelines, CSP was achieved if the lower
bound of the 95% CI was greater than 80%. The lower
bound of the 95% CI for the ITT group was 90.1%.Filter Retrieval
Sixteen sites performed 114 screenings for possible ﬁlter
retrieval in 111 patients. Vena cava angiograms revealed
thrombus in three ﬁlters. These three patients were
administered anticoagulation and returned for a second
screening venogram that revealed no thrombus. Their
ﬁlters were then removed successfully. One hundred
eight of 111 retrieval attempts were successfully com-
pleted and three retrievals failed, resulting in a technical
success rate of ﬁlter retrieval of 97.3%. In two cases, the
investigator was unable to engage the ﬁlter apex with a
snare; core laboratory measurements revealed that nei-
ther device tilted, migrated, or penetrated the caval wall.
One additional device was engaged with a snare but
could not be completely collapsed in to the sheath as a
result of thrombus in the IVC, so the ﬁlter could not be
removed. In these three cases, the ﬁlter was left in place
as a permanent device. The clinical success rate of
retrieval—ie, successful retrieval without complications
—was 99.1% (107 of 108). Of the 108 successful
retrievals, ﬁlters were retrieved intact in all cases. In
one case, retrieval of the ﬁlter resulted in intimal injury
with caval narrowing. The ﬁlter was removed intact, but
the patient was hospitalized overnight for observation
and required no further intervention. No DVT or IVC
thrombus has developed in this patient.
The mean ﬁlter indwell time for the 108 successfully
retrieved ﬁlters was 165.0 days  113.9 (median, 147 d;
range, 5–632 d), with 39.8% of ﬁlters retrieved at later
than 6 months (Fig 3). The mean retrieval procedure
time was 21.3 minutes  15.7 (range, 4–118 min), and
the mean ﬂuoroscopy time for successful retrieval was
6.4 minutes  8.61 (range, 1–69 min; Table 2). The right
internal jugular vein was used for all retrieval
procedures. Fifty patients (46.3%) who underwent ﬁlter
retrieval had an indication for ﬁlter placement involving
active thromboembolic disease (ie, DVT and/or PE at
the time of placement); 58 patients (53.7%) who had
Patients Implanted
n=200
Retrieved Patients:
Lost to follow-up: 2
30-day follow-up: 104
30-day follow-up not
completed: 2
Retrieved
Successfully
n=108
Follow-Up
YesRetrieval Attempted n=111n=89
Not 
Retrieved
n=3
No
No
Filter In Situ
n=92
Nonretrieved Patients:
Lost to follow-up: 5
Withdrawn: 3
Deaths: 14
6-month follow-up: 49
6-month follow-up not 
completed: 21
Nonretrieved Patients:
12-month follow-up: 47
18-month follow-up: 27
24-month follow-up: 7
Retrieved Patients:
6-month follow-up: 39
Figure 2. Disposition of the 200 patients in the Denali IVC ﬁlter trial.
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placement but had no active thromboembolic disease.Overall Clinical Experience
The rates of recurrent PE, new or worsening DVT, ﬁlter
fracture, migration (4 2 cm), penetration (4 3 mm),
and tilt (4 151) were evaluated and are presented in
Table 4. The rate of recurrent PE was 3.0% (six of 200;
95% CI, 1.1%–6.4%). Five patients presented with small
PEs located in the segmental and/or subsegmental
vasculature; symptoms were not consistent with higher-
risk PEs (eg, no signs of hypotension and/or signs of
right ventricular dysfunction). One patient had PE
associated with hypotension as well as right ventricular
dysfunction along with an intractable hypercoagulable
state possibly as a result of advanced malignancy; the
patient subsequently died. New or worsening DVT was
deﬁned as an extension of existing DVT to a new venous
segment in patients who had DVT at baseline, or new
DVT in patients who did not exhibit signs at baseline
(both determined by follow-up imaging). The rate of newor worsening DVT was 12.8% (95% CI, 8.3%–18.7%),
including 26 instances of DVT in 23 patients, with 19
instances of new DVT and seven instances of worsening
DVT. All reports of new DVT occurred in patients who
had active thromboembolic disease at baseline, were
considered to be in a hypercoagulable state, had expe-
rienced multiple-trauma injuries, or had lower-extremity
orthopedic procedures.
There were no instances of IVC ﬁlter fracture, ﬁlter
migration, or ﬁlter tilt greater than 151 in the DENALI
trial. There were ﬁve instances (2.5%) of penetration of ﬁlter
arms or legs more than 3 mm beyond the vena cava wall
seen on venography (core laboratory–adjudicated): three
instances noted at implantation and two at the time of ﬁlter
retrieval. None of the reported penetrations were sympto-
matic, and the ﬁlter was subsequently retrieved or continued
to be followed with no reported clinical sequelae.Safety
A total of 148 patients had one or more adverse events
(AEs) reported during the course of the study. An AE
Volume 25 ’ Number 10 ’ October ’ 2014 1503was deﬁned as an untoward medical occurrence regard-
less of the relationship to the study device or procedure.
The independent CEC adjudicated all AEs and
determined that 13 (6.5%) were possibly or deﬁnitely
related to the procedure and nine (4.5%) were possibly
or deﬁnitely related to the ﬁlter (Table E1, availableTable 3 . Clinical Success of Filter Placement and Retrieval
Variable Value
Placement success*
Clinical success of placement† 172 (94.5)
95% CI 90.1–97.3
Recurrence of PE 6 (3.0)
Filter embolization 0
Vena cava occlusion‡ 1 (1.0)
Filter/procedure-related death 0
Insertion adverse event 3 (1.5)
Technical failure 1 (1.0)
Retrieval success§
Clinical success of retrieval 107 (99.1)
95% CI 94.9–100
Retrieval complications
Required intervention 1 (1.0)
Values in parentheses are percentages.
CI ¼ conﬁdence interval, PE ¼ pulmonary embolism.
*Clinical success of ﬁlter placement was deﬁned as freedom
from subsequent PE, ﬁlter embolization, vena cava occlusion,
ﬁlter- or procedure-related death, adverse events associated
with ﬁlter placement, or failure of ﬁlter placement.
†Interim intent-to-treat population consisted of 182 patients;
172 patients had clinical success of ﬁlter placement.
‡This patient was reported as a recurrent PE. There were 11
events in 10 patients.
§Successful technical retrieval of the ﬁlter without retrieval
complications.
Figure 3. Dwell time for retrieved IVC ﬁlters.online at www.jvir.org). Seventy-nine patients experi-
enced serious AEs requiring inpatient medical care.
The CEC determined that four (2.0%) were possibly or
deﬁnitely related to the procedure and seven (3.5%)
were possibly or deﬁnitely related to the ﬁlter. Four-
teen patients died during the course of the study fromTable 4 . Overall Clinical Experience
Variable Incidence 95% CI
Recurrent PE* 6/200 (3.0) 1.1–6.4
DVT 23/179† (12.8) 8.3–18.7
New DVT‡ 19/179 (10.6) –
Worsening DVT§ 7/179 (3.9) –
Filter complications||
Filter fracture 0/179 0.0–2.0
Filter migration (4 2 cm) 0/179 0.0–2.0
Filter penetration (4 3 mm) 5/200 (2.5) 0.8–5.7
Penetration at placement 3/200 (1.5) 0.3–4.3
Penetration at retrieval¶ 2/113 (1.8) 0.2–6.2
Tilt 4 151 0/200 0.0–1.8
CI ¼ conﬁdence interval, DVT ¼ deep vein thrombosis, PE ¼
pulmonary embolism.
*Clinical diagnosis of recurrent PE was conﬁrmed by pulmon-
ary arteriography, cross-sectional imaging, altered ventilation/
perfusion lung scan, or at autopsy.
†All patients with imaging after baseline (n ¼ 179).
‡New DVT, based on imaging, in patients who had no DVT at
baseline.
§Extension of existing DVT, based on imaging, to a new
venous segment in patients who had DVT at baseline.
||Core laboratory evaluated all implant, retrieval, and 6-month
images.
¶Rate of penetration based on 111 attempted retrievals and
two cases in which the ﬁlter was screened for retrieval but an
attempt was not made.
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cated by the CEC as unrelated to the device or
procedure.DISCUSSION
In the present interim analysis of the 200 patients enrolled
in the DENALI IVC ﬁlter trial, clinical success of ﬁlter
placement was achieved in 94.5% of patients. The
deﬁnition of clinical success in this trial was conservative,
as three cases were classiﬁed as clinical failures based on
the patients having self-limited pain at the access site after
ﬁlter placement. The pain resolved in all three patients
without treatment, and there was no access-site DVT in
any of the three patients. Without these three patients
included as cases of clinical failure, clinical success would
have been achieved in 96.2% of patients. Six of the clinical
failures were caused by PE. The PE rate of 3% in the
DENALI trial was within the established threshold value
of 5% (19). PE rates from 1% to 6% have been reported in
similar IVC ﬁlter trials (11,14,15,17). Signiﬁcantly, there
were no instances of IVC ﬁlter fracture, migration, or
ﬁlter tilt greater than 151. There were 19 instances of new
DVT (9.5%), which this also compares favorably with the
ﬁndings of recent similar IVC ﬁlter clinical trials
(11,14,15,17). The ﬁve instances of ﬁlter penetration in
the trial (2.5%) were deﬁned as penetration greater than 3
mm on venography. This deﬁnition was similar to those
of other IVC ﬁlter trials, but can result in IVC wall
“tenting” being overestimated as penetration or perfora-
tion. The more accurate CT-based grading system for
IVC penetration, described by Oh et al (23), for ﬁlter
penetration and perforation was not used in the present
study. There were no instances of symptomatic ﬁlter strut
penetration or perforation.
Of the 111 patients who underwent a ﬁlter retrieval
attempt, 108 (97.3%) had their ﬁlter successfully ret-
rieved. Two of the ﬁlters could not be retrieved because
the investigator was unable to negotiate a snare around
the hook of the ﬁlter. Other nonstandard ﬁlter retrieval
techniques such as forceps retrieval or the loop-snare
technique were not used. Review of the retrieval images
by the core laboratory revealed that these two ﬁlters
were not signiﬁcantly tilted and the ﬁlter tips were not
embedded in the wall of the IVC. The failure to engage
the hook was believed by the investigator to be a result
of AP angulation of the IVC. This AP angulation did
not allow the hook of the ﬁlter to be snared, and both of
these ﬁlters were left in place as permanent devices.
There was one patient who had asymptomatic IVC
narrowing after ﬁlter retrieval. The patient remained
asymptomatic but was admitted overnight for observa-
tion. No other complications occurred as a result of ﬁlter
retrieval.
A potentially clinically relevant ﬁnding of the
DENALI trial was the long dwell times after whichﬁlters were retrieved. Mean indwell time of the retrieved
ﬁlters was 165 days, and the maximum dwell time for a
ﬁlter that was retrieved was 632 days. There were no
retrieval failures related to incorporation of the ﬁlter
struts in the wall of the IVC or the ﬁlter hook being
embedded in the IVC. These are two of the most
common causes of ﬁlter retrieval failures in currently
used devices, and can increase in frequency the longer
the ﬁlters are in place (24). The ability to retrieve IVC
ﬁlters after long dwell times is a desirable quality for
retrievable ﬁlters because it could potentially allow for a
higher percentage of ﬁlters to be removed. An FDA com-
munication in August 2010 (25) warned of the adverse
events that could occur to patients with retrievable ﬁlters
that are not removed. Implanting physicians were
encouraged by the FDA to follow their patients closely
and remove the ﬁlters when they are no longer needed for
PE protection. Filters that can be removed after a prolonged
period of time will potentially have the advantage of inc-
reasing the number of ﬁlters that can ultimately be removed.
Although a retrievable ﬁlter with a long potential dwell time
is advantageous, this is no substitute for close follow-up of
all patients with IVC ﬁlters and removal of ﬁlters as soon as
PE protection is no longer required.
Limitations to the present study exist. Although the
DENALI trial was a prospective multicenter study, the
nonrandomized single-arm design introduces some lim-
itations. A potential for bias exists in any manufacturer-
sponsored device trial. This is an interim analysis, and
not all patients have been followed for 2 years, as will be
the case when the study is concluded. However, the
study was designed to enroll 200 patients, and all of
them have been included in the present analysis. In
addition, the follow-up is longer, and the number of
patients included is greater, in this interim analysis than
in many similar trials (11,14,15,17). As with other IVC
ﬁlter studies, the PE rate could be underestimated in the
present trial. This is because imaging for PE was done in
only patients who had clinical symptoms that were
suggestive of PE. PE imaging was not done in every
patient, and additional patients with asymptomatic PEs
may have gone undetected.
In the present interim analysis of the DENALI trial
data, the Denali IVC ﬁlter has shown a high rate of
clinical success with a low complication rate within the
thresholds suggested by SIR, which compare favorably
to data from similar clinical IVC ﬁlter trials
(11,14,15,17,19). The ability to remove the ﬁlter after
relatively prolonged dwell times shown in the present
trial has the potential to increase ﬁlter retrieval rates as
clinical use of this device increases.ACKNOWLEDGMENTS
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Table E1 . Adverse Events by System Organ Class
Category Patients with Z 1 AE Device-Related AEs* Procedure-Related AEs*
All patients, all adverse events† 148 (74.0) 9 (4.5) 13 (6.5)
Blood and lymphatic system disorders 31 (15.5) 0 0
Cardiac disorders 30 (15.0) 0 0
Congenital, familial, and genetic disorders 1 (0.5) 0 0
Ear and labyrinth disorders 1 (0.5) 0 0
Gastrointestinal disorders 61 (30.5) 1 (0.5) 0
Eye disorders 6 (3.0) 0 0
General disorders and administration site conditions 44 (22.0) 2 (1.0) 2 (1.0)
Hepatobiliary disorders 6 (3.0) 0 0
Immune system disorders 3 (1.5) 0 0
Infections and infestations 58 (29.0) 0 0
Injury, poisoning, and procedural complications 27 (13.5) 1 (0.5) 3 (1.5)
Investigations 15 (7.5) 0 0
Metabolism and nutrition disorders 24 (12.0) 0 0
Musculoskeletal and connective tissue disorders 53 (26.5) 2 (1.0) 6 (3.0)
Neoplasms benign, malignant, and unspeciﬁed
(including cysts and polyps)
12 (6.0) 0 0
Nervous system disorders 32 (16.0) 0 0
Psychiatric disorders 8 (4.0) 0 0
Renal and urinary disorders 25 (12.5) 0 0
Reproductive system and breast disorders 5 (2.5) 0 0
Respiratory, thoracic, and mediastinal disorders 30 (15.0) 1 (0.5) 0
Skin and subcutaneous tissue disorders 16 (8.0) 0 1 (0.5)
Surgical and medical procedures 1 (0.5) 0 0
Vascular disorders 42 (21.0) 3 (1.5) 1 (0.5)
The table lists AEs by Medical Dictionary for Regulatory Activities preferred terms.
Values in parentheses are percentages.
AE ¼ adverse event.
nAEs were adjudicated and classiﬁed by the independent clinical events committee.
†The denominator is 200 enrolled patients. Some patients had adverse events in one or more category.
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